title: Reply to: Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant.
authors.affiliation: 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece. cholongitas@yahoo.gr.
authors.forename: Evangelos
authors.initials: E
authors.lastname: Cholongitas
authors.forename: Patrizia
authors.initials: P
authors.lastname: Burra
mesh_terms: D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D020123:Sirolimus / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus